Linked Life Data

1834014

Source:http://linkedlifedata.com/resource/pubmed/id/1834014

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
1991-11-1
pubmed:abstractText
A teicoplanin fluorescence polarization immunoassay (FPIA) developed by International BioClinical (IBC) was evaluated by using serum samples from patients who had been receiving teicoplanin at Detroit Receiving Hospital (DRH) as part of a clinical investigation. Patient samples collected over a 1-year span were assayed at DRH and at IBC, and the results were compared with those of a standard microbiological assay performed at Merrell Dow Research Institute, Indianapolis, Ind. The FPIA has a rapid turnaround time (circa 20 min), utilizes small sample volumes (less than 100 microliters) and is sensitive and accurate in determining concentrations in the range of 5 to 100 micrograms/ml. The intra-assay and interassay coefficient of variation for controls (7, 35, and 75 micrograms/ml) was less than or equal to 13%. Concentrations greater than 100 micrograms/ml must be diluted prior to the assay, which may introduce additional error in determination. The FPIA compared well with the bioassay (r = 0.901) for 193 clinical samples. The results obtained utilizing the FPIA system were reproducible at two different sites, as illustrated by the high degree of correlation between the results at DRH and IBC (r = 0.92). There was less than 7% interference noted when teicoplanin was assayed in the presence of other antibiotics. Patient samples stored for up to 1 year retained their potency: the mean recovery rate in these samples was 107%. The FPIA should be useful for monitoring and adjusting teicoplanin dosage regimens in patients.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/1834014-1826594, http://linkedlifedata.com/resource/pubmed/commentcorrection/1834014-1829880, http://linkedlifedata.com/resource/pubmed/commentcorrection/1834014-2140496, http://linkedlifedata.com/resource/pubmed/commentcorrection/1834014-2529097, http://linkedlifedata.com/resource/pubmed/commentcorrection/1834014-2533051, http://linkedlifedata.com/resource/pubmed/commentcorrection/1834014-2871091, http://linkedlifedata.com/resource/pubmed/commentcorrection/1834014-2942100, http://linkedlifedata.com/resource/pubmed/commentcorrection/1834014-2952062, http://linkedlifedata.com/resource/pubmed/commentcorrection/1834014-2957953, http://linkedlifedata.com/resource/pubmed/commentcorrection/1834014-2965132, http://linkedlifedata.com/resource/pubmed/commentcorrection/1834014-6240962, http://linkedlifedata.com/resource/pubmed/commentcorrection/1834014-7321548
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0066-4804
pubmed:author
pubmed:issnType
Print
pubmed:volume
35
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1586-90
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1991
pubmed:articleTitle
Clinical evaluation of teicoplanin fluorescence polarization immunoassay.
pubmed:affiliation
College of Pharmacy and Allied Health Professions, Wayne State University, Detroit, Michigan.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, Non-U.S. Gov't